A large national cohort study shows that serious medical illness independently raises suicide risk—even without prior psychiatric diagnosis. Gastrointestinal disease, cancer, and blood disorders stand out. For hospitalized patients with new or disabling medical conditions, suicide screening and safety planning remain essential parts of care.

Do antipsychotics during pregnancy increase long-term neurodevelopmental risk? Large US and Nordic registry studies, along with prospective data, provide reassuring findings. After adjusting for maternal illness, prenatal exposure was not meaningfully associated with intellectual, language, or learning disorders—important context for shared decision-making.

When should you suspect a genetic syndrome in an adult psychiatric patient? This review highlights red flags—autism, intellectual disability, dysmorphic features, family patterns—and walks through practical testing strategies. Learn when to order chromosomal microarray and Fragile X testing, and how results can reshape treatment and family counseling.

The FDA has approved the first at-home brain stimulation device for major depressive disorder. What does this mean for access, oversight, and patient selection? Dr. Victoria Hendrick reflects on how this newly approved headset could expand neuromodulation—while raising important clinical and reimbursement questions for hospital psychiatrists.

Is ketamine really more effective than an active placebo for inpatient depression? A new randomized trial puts ketamine head-to-head with midazolam, and the results may temper early enthusiasm.

Can continuation and maintenance ECT (c/mECT) reduce hospitalizations and healthcare costs? A large Danish study suggests it can, especially for patients with schizophrenia or treatment-resistant illness. Explore how c/mECT could reshape long-term care planning for your most complex cases.

There is no cure for major neurocognitive disorder (MND), but several medications mitigate the progression of cognitive and functional decline.